Overview

Treatment of Post-Ocriplasmin Therapy Vitreolysis Induced Subretinal Fluid With Eplerenone (Mineralocorticoid Antagonists)

Status:
Terminated

Trial end date:
2021-01-05

Target enrollment:

Participant gender:

Summary

Evaluate the efficacy of eplerenone as an adjunctive treatment to intravitreal ocriplasmin for subretinal fluid in comparison to a control group of only receiving intravitreal ocriplasmin in patients with symptomatic vitreomacular adhesion.

Phase:

Phase 2

Details

Lead Sponsor:

Wagner Macula & Retina Center

Collaborator:

ThromboGenics

Treatments:

Eplerenone
Mineralocorticoid Receptor Antagonists
Mineralocorticoids